NeuroTalk Support Groups - anyone ever use doxepin/seraquel?

NeuroTalk Support Groups (https://www.neurotalk.org/)

- Peripheral Neuropathy (https://www.neurotalk.org/peripheral-neuropathy/)

- - anyone ever use doxepin/seraquel? (https://www.neurotalk.org/peripheral-neuropathy/108784-doxepin-seraquel.html)

I will only take Seroquel for short periods of time (3-7 days).
I know this is not generally a good therapeutic time, but it helps me.

I'm not bi-polar, I have mood disorder NOS, and a personality disorder known as borderline personality disorder (BPD).

*not things I'm particularly proud of, but I have a feeling its genetic since my mother and sister are both a few crayons short of a box*

I won't stay on Seroquel due to its nasty side effect of weight gain.

Can't say I've had any side effects you've mentioned though.

And I've tried both aformentioned medications.

I think Dr. Sarno is fascinating. I have read one of his books.

You know what is happening with my leg pain and back pain?
I started arginine/citrulline to help my blood pressure and cold feet, and it is improving circulation to my old injuries, and the nagging problems I have had since my leg injury have gone away.

Dr. Sarno believes that emotions trigger vasoconstriction in places --I have to wonder if that is reversed by these two amino acids which raise nitric oxide? It has been about 2 months into my
experiment with them. So far I only have some heartburn to show for them, as negative. The positives have been really nice so far.

This just posted on our Healthnews headlines forum:

http://psychcentral.com/news/2009/12...meds/9888.html

In addition to hyperglycemia and hyperlipidemia are these findings:

Quote:

Their findings provide evidence that antipsychotic medications, particularly olanzapine (Zyprexa®, Eli Lilly and Co.) and quetiapine (Seroquel®, AstraZeneca), increase the levels of inflammation markers.

The markers implicated include C-reactive protein, E-selectin, and intercellular adhesion molecular-1 (ICAM-1).

Increased levels of C-reactive protein in particular are associated with increased risk for the development or progression of many illnesses including heart disease, and stroke.

“This analysis provides the most compelling evidence to date that differences in antipsychotic metabolic liability are also seen with markers of systemic inflammation,” explained Dr. Meyer. “It also provides an impetus for monitoring cardiovascular risk markers in antipsychotic treated patients.”